Holla_Sittingbourne
@edunsky · X
Semaglutide (Ozempic & Wegovy) Explained: The Risks, Side Effects, and Ethics: - https://t.co/JMWt94ExjF
Jul 17, 2025 · 1 like · 9,019 followers
View post →
October 2014 PMID 25338737
Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists.
Mentions
6
Peak: 2 in Jul 2025
across 3 sources since Apr 2023
Extended reach
64,018
potential audience
Total likes
779
Video views
49,383
Mentions per month
Apr 2023 – Jul 2025Where it's discussed
-
X / Twitter2 posts
-
YouTube2 videos
-
Facebook2 posts
AI synopsis
What people are saying
The discussions demonstrate a high level of interest in the cardiovascular effects of GLP-1 receptor agonists, with statements like 'bioplausible' benefits and questions about underlying mechanisms. The tone is inquisitive, reflecting an engagement that balances support and scientific curiosity, but without asserted definitive impact on treatment guidelines.
AgreementModerate agreement
The discussion suggests a cautious agreement, citing prior observations that support the cardiovascular benefits of GLP-1 receptor agonists but with a note of scientific curiosity.
InterestHigh interest
The topic of cardiovascular effects of diabetes medications naturally attracts high interest, especially with ongoing debates about safety and efficacy.
EngagementModerate engagement
The discussion reflects some engagement, referencing specific studies and asking about mechanisms, indicating a thoughtful consideration of the research.
ImpactNeutral impact
While the discussion shows interest and some agreement, it does not indicate immediate or substantial impact on clinical practice yet.
Abstract in brief
- Patients with type 2 diabetes face a significantly higher risk of cardiovascular disease, including myocardial infarction and stroke, which are leading causes of death in this population.
- Advances in risk management, such as better control of LDL cholesterol with statins, have reduced acute cardiovascular events, highlighting diabetes as a major contributor to cardiovascular issues.
- Glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of diabetes medications that not only lower blood sugar but also have protective cardiovascular effects, support neuronal health, reduce inflammation, promote weight loss, and improve insulin sensitivity.]
Top posts
Most liked on X and Bluesky
DSDevan Sinha
@DevanSinha · X
@AAMortazavi There's been multiple observations from GLP-1 infusion studies in periop patients or murine models to show quick onset extensive cardiovascular effects. So MACE/ACM clinical benefit is bioplausible. Curious which signalling/effector axis involved if true https://t.co/V7v5d34Nbz
Nov 11, 2023 · 5,616 followers
View post →
All mentions
Understanding the Cardiovascular Benefits of GLP-1 Receptor Agonists
Patients with type 2 diabetes face a significantly higher risk of cardiovascular disease. GLP-1 receptor agonists not only lower blood sugar but also offer protective cardiovascular effects and support overall health.
Dr. Hong's Pharmacy Classroom · Apr 9, 2023
49,263 views
Semaglutide's Impact on Weight Loss and Cardiovascular Health Explained
This video breaks down how semaglutide works inside the body. We explore its effects on hunger, blood sugar, and long-term weight loss, along with potential side effects and cardiovascular benefits supported by recent…
Live Longer Live Better · Jul 13, 2025
120 views
Holla_Sittingbourne
@edunsky · X
Semaglutide (Ozempic & Wegovy) Explained: The Risks, Side Effects, and Ethics: - https://t.co/JMWt94ExjF
Jul 17, 2025 · 1 like · 9,019 followers
View post →
Devan Sinha
@DevanSinha · X
@AAMortazavi There's been multiple observations from GLP-1 infusion studies in periop patients or murine models to show quick onset extensive cardiovascular effects. So MACE/ACM clinical benefit is bioplausible. Curious which signalling/effector axis involved if true https://t.co/V7v5d34Nbz
Nov 11, 2023 · 5,616 followers
View post →
No mentions from this source yet.